Gradients
A mechanistic science of human flourishing
Abolishing drug tolerance with next-generation therapeutics
The Thesis
AI is radically accelerating all parts of the drug development pipeline, from discovery to experimental validation. What used to take a decade and a billion dollars is becoming faster and cheaper, and soon enough by orders of magnitude. We are on a mission to leverage breakthroughs in AI for developing therapeutics for pain, well-being, and other indications, with no tolerance or withdrawal, and vastly improved side-effect profiles.
Team
Leadership
Curran Jansens
Co-Founder & CEO
Max Novendstern
Co-Founder & Chairman
David Pearce
Bioethics Director
Michael Johnson
Advisor
Kristian Rönn
Advisor